Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Overview
Explore Madrigal Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
10.1B
P/E Ratio
-34.53
EPS (TTM)
$-12.85
ROE
-0.44%
MDGL Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Madrigal Pharmaceuticals, Inc. (MDGL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 42.05, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $525.71.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -34.53 and a market capitalization of 10.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.